Demographical and Clinical Profile of Patients With Left Ventricular Hypertrophy

NCT04275882 | Completed

• 1 other identifier: LVH-TR
• Study Type: observational
• Target: 886
• Locations: 1 country
• Sites: 1

Brief Summary

Left ventricular hypertrophy (LVH) is the most common result of the heart trying to pump blood against the high afterload, as in hypertension and aortic stenosis.Although hypertension is the most common cause of LVH, LVH can also be found in athletes and cardiomyopathies or in storage disorders such as amyloidosis. In addition, genetic diseases also play an important role in the pathogenesis of LVH. Fabry disease is another disease that should be considered in patients with left ventricular hypertrophy.Left ventricular hypertrophy is a common and potentially modifiable cardiovascular risk factor that is frequently overlooked in clinical practice.The benefit of combining ECG and echocardiography in the diagnosis of LVH has been demonstrated.Early diagnosis and treatment-related regression of LVH, reduces adverse cardiovascular events and improves survival.Therefore, the investigators planned to perform a retrospective, observational LVH-TR study in order to determine the etiologic causes of LVH, the symptoms presented by the patients, and the effects of patients' demographic characteristics on LVH.

Conditions

Left Ventricular Hypertrophy

Keywords

Echocardiography; retrospective; electrocardiography; hypertension; cardiomyopathy

Outcome Measures

Primary Outcomes (2)

• Demographic characteristics

  Demographic characteristics of patients with left ventricular hypertrophy (LVH) on ECG and / or echocardiography

  6 months

• Evaluation of etiologic data

  Evaluation of etiologic data of patients with left ventricular hypertrophy (LVH) on ECG and / or Echocardiography

  6 months

Other Outcomes (1)

• Frequency of Fabry and Amyloidosis

  6 months

Interventions

Electrocardiogram DIAGNOSTIC_TEST

There will be no new intervention performed for the patients.

Also known as: Echocardiography

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients admitted to cardiology clinics and / or outpatient clinics with left ventricular hypertrophy (LVH) detected by ECG and / or echocardiography will be included retrospectively.

You may qualify if:

• Patients who have undergone ECG / ECO within the last 6 months and have been found to meet LVH according to the specified criteria
• older than 18 years and younger than 90 years
• who signed the informed consent form

You may not qualify if:

• Cases without optimal electro or echocardiographic examination due to limited echogenicity

Sponsors & Collaborators

• Cardiovascular Academy Society, Turkey: lead

Study Sites (1)

Yasemin

Kayseri, Eyalet/Yerleşke, 38000, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Hypertrophy, Left Ventricular; Hypertension; Cardiomyopathies

Interventions

Electrocardiography; Echocardiography

Condition Hierarchy (Ancestors)

Cardiomegaly; Heart Diseases; Cardiovascular Diseases; Hypertrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Vascular Diseases

Intervention Hierarchy (Ancestors)

Heart Function Tests; Diagnostic Techniques, Cardiovascular; Diagnostic Techniques and Procedures; Diagnosis; Electrodiagnosis; Cardiac Imaging Techniques; Diagnostic Imaging; Ultrasonography

Study Officials

• mehmet kış, dr

  turkey

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: prof.dr.

Study Record Dates

• First Submitted: February 17, 2020
• First Posted: February 19, 2020
• Study Start: February 14, 2020
• Primary Completion: September 1, 2021
• Study Completion: December 1, 2021
• Last Updated: March 8, 2022

Record last verified: 2021-08

Locations

TU (1)